Navigation Links
Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer

New York, New York (PRWEB) June 07, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the victims of defective drugs, has filed a lawsuit on behalf of a Pennsylvania man who allegedly developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23rd in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1170) as part of the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff started taking Actos in November 2003 to treat his Type 2 diabetes. By August 2006, he was diagnosed with bladder cancer. The suit alleges that Actos caused the bladder cancer due to its defective nature. Furthermore, the suit alleges that the Defendants knew about the risk of bladder cancer but failed to disclose this information to consumers in order to protect financial interests. The Plaintiff is alleging that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk*. Additional research supports the link between Actos and bladder cancer. Last May, a study in the British Medical Journal** found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal*** found that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLC Applauds Seniors for their Role in Helping to Recover $14.9 billion in Medicare Fraud over the Past Four Years
2. Parker Waichman LLP’s Jordan Chaikin Is Appointed to the Executive Committee of the Plaintiff’s Leadership Team in Emerson Electric Co. Wet/Dry Vac Litigation
3. Woman with Bilateral DePuy Pinnacle Hip Implant Alleges Metal Hips are Flawed in Lawsuit Filed by Parker Waichman LLP
4. Atlantic City Hotel’s Negligence Caused Conditions that Led to Serious Injuries, Alleges Lawsuit Filed by Parker Waichman LLP
5. Parker Waichman LLP Files Appeal over the Pennsylvania Department of Environmental Protection’s Ruling that Natural Gas Wells Did not Harm Couple's Drinking Water Supply
6. Parker Waichman LLP Designated as Co-Lead Counsel in the Consolidation of Hurricane Sandy-related Litigation Against the Long Island Power Authority and/or National Grid
7. Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
8. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
9. Mirena IUD Lawsuit Update: Supreme Court of New Jersey Centralizes Litigation; Parker Waichman LLP Underscores the Advantages of this Decision
10. DePuy Pinnacle Hip Implant Caused Elevated Ion Levels, Revision Surgery, Alleges Lawsuit Filed by Parker Waichman LLP
11. DePuy ASR Lawsuit Update: Parker Waichman LLP Commends Judge’s Refusal of Appeal for New Trial; DePuy Still Must Pay $8.3 Million Verdict
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Center of Excellence (BHCOE) today announced that the organization has awarded Education and ... Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers that ...
(Date:12/1/2015)... ... , ... McLean, VA., December 1, 2015 - Octo Consulting ... agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services Directorate. ... infrastructure, as well as operations and sustainment support to the NGA’s Agile Web ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
(Date:12/1/2015)... ... ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - Extreme ... 2016, the world’s largest Consumer Electronic Show, where they will present to a panel ... Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top names ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015   Nottingham Spirk , ... announced the publication of a free whitepaper ... Medical Market". The whitepaper gives medical product companies, ... penetrating this lucrative segment. Nottingham Spirk ... to manage their own health, save money (i.e., ...
(Date:12/1/2015)... 2015 Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... Conference in New York.  The public is ... a webcast on the Array BioPharma website. ... --> , --> ...
(Date:12/1/2015)... , BANGALORE, India and ... N.V. (NASDAQ, TASE: MYL) today announced that it expects ... and for developing country markets funded by international donors, ... mg + Efavirenz 400 mg) for $99 per patient, ... Initiative (CHAI) to develop TLE400. The significantly reduced price ...
Breaking Medicine Technology: